Compare KKR & Co Inc (KKR) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs McKesson Corporation — how do they compare? KKR & Co Inc trades at $96.97 (market cap $87.07B), while McKesson Corporation trades at $832.45 (market cap $97.35B). The key difference: KKR & Co Inc and McKesson Corporation are close in size by market cap, and KKR & Co Inc pays the higher dividend (0.77%). Which is the better fit depends on your goals.
| KKR | MCK | |
|---|---|---|
Market Cap | $87.07B | $97.35B |
Sector | Financials | Health |
52-Week High | $152.16 | $995.69 |
52-Week Low | $83.88 | $659.01 |
Enterprise Value | $12.59B | $101.98B |
Dividend Yield | 0.77% | 0.39% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
